DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actigall (Ursodiol) - Published Studies

 
 



Actigall Related Published Studies

Well-designed clinical trials related to Actigall (Ursodiol)

Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011.09]

Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. [2008.07.09]

Well-designed clinical trials possibly related to Actigall (Ursodiol)

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. [2014]

[Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial]. [Article in Korean] [2014]

Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. [2013]

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. [2012]

Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. [2012]

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]

A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. [2011.05.12]

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. [2011.05]

Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. [2011]

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. [2010.08]

Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. [2010.08]

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. [2010.07]

NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. [2010.05]

The predictors of the presence of varices in patients with primary sclerosing cholangitis. [2010.04]

Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. [2010.02]

[Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B]. [2010.02]

Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. [2010.01]

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. [2010]

Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. [2010]

Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. [2009.12]

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. [2009.09]

Physical activity as a determinant of fecal bile acid levels. [2009.05]

Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. [2009.04]

Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: A multicenter, randomized, double-blind clinical trial. [2008.08.12]

Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: A multicenter randomized controlled trial. [2008.03]

Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. [2008.02]

Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. [2008.02]

Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. [2008.02]

Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. [2007.08.28]

Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. [2007.08]

Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. [2007.06.27]

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. [2006.12]

Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. [2006.09.15]

Effects of choleretics on bile compositions drained from patients with pigment gallstone. [2006.06]

Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. [2006.06]

[Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)] [2006.03]

Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. [2006]

Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. [2005.12]

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. [2005.11]

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. [2005.11]

Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. [2005.10]

Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. [2005.09]

Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. [2005.08]

Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. [2005.08]

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. [2005.06.01]

Karyometry in rectal mucosa of patients with previous colorectal adenomas. [2005.06]

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. [2005.04]

Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. [2005.03.15]

Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease. [2005.01]

Other research related to Actigall (Ursodiol)

Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011]

Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. [2010.08]

Ursodiol in patients with parenteral nutrition-associated cholestasis. [2007.11]

Ursodiol in Patients with Parenteral Nutrition-Associated Cholestasis (November). [2007.10.02]

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. [2005.01]

Other possibly related research studies

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplantation. [2007.02]

Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. [2007.01.11]

Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. [2006.12]

[Effects of resolving phlegm method on fibrinolytic status in non-alcoholic steatohepatitis patients of phlegm and blood-stasis syndrome] [2006.12]

Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. [2006.12.21]

Gallstone disease: Primary and secondary prevention. [2006]

Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. [2006.12]

Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. [2006.10]

[Granulomatous hepatitis successfully treated with ursodeoxycholic acid] [2006.08.06]

Ursodeoxycholic acid in the treatment of intraheptic cholestasis of pregnancy. [2006]

Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. [2006.10]

Primary sclerosing cholangitis: summary of a workshop. [2006.09]

Molecular mechanisms of cholestasis. [2006.07]

Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. [2006.05.03]

Routine gallbladder screening not necessary in patients undergoing laparoscopic Roux-en-Y gastric bypass. [2006.01]

Retrospective review of the preoperative biliary and gastrointestinal evaluation for gastric bypass surgery. [2006.01]

Incidence of symptomatic gallstones after gastric bypass: is prophylactic treatment really necessary? [2005.11]

Elective cholecystectomy after Roux-en-Y gastric bypass: why should asymptomatic gallstones be treated differently in morbidly obese patients? [2005.11]

Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. [2006.06]

Deflazacort for type-1 autoimmune hepatitis in a Korean girl. [2006.08]

Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. [2006.07]

Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. [2006.09]

Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. [2006.09.14]

Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. [2006.07.15]

Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. [2006.05]

Chemoprevention for colon cancer: new opportunities, fact or fiction? [2006.05]

Ursodeoxycholic acid treatment of vanishing bile duct syndromes. [2006.06.14]

Parenteral nutrition-associated liver disease in adult and pediatric patients. [2006.06]

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. [2006.06]

[Predisposing factors and results of pharmalogical treatment using ursodeoxycholic acid of gallbladder stones in children] [2006.02]

Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. [2006.03]

Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. [2006.05]

Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. [2006.03]

Treatment of nonalcoholic fatty liver disease. [2006.04.14]

Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. [2005]

Primary biliary cirrhosis: when and why does the disease develop? [2006.04]

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. [2006.03]

Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation. [2006]

Primary sclerosing cholangitis: diagnosis and management. [2006.02]

Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids. [2005.11]

The medical management of primary sclerosing cholangitis. [2006.02]

Autoimmune hemolytic anemia in an infant with giant cell hepatitis. [2006.03]

3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. [2006.07.15]

Dexamethasone in the treatment of obstetric cholestasis: a case series. [2006.02]

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. [2006.02]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017